Recent News

• 03.06.2025 - bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
• 02.26.2025 - bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
• 02.25.2025 - bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
• 01.22.2025 - bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
• 01.22.2025 - bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
• 01.13.2025 - bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
• 01.13.2025 - bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Recent Filings

• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 8-K Current report
• 02.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.07.2025 - 8-K Current report
• 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2025 - 8-K Current report